Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention.

[1]  J. Miller,et al.  A Concise History of Mycotoxin Research. , 2017, Journal of agricultural and food chemistry.

[2]  A. Bertoletti,et al.  Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks , 2017, Viruses.

[3]  R. Schwartz,et al.  Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. , 2016, Current opinion in virology.

[4]  M. Sherman.  Hepatitis B Vaccination: Putting Hepatologists Out of Business? , 2016, Gastroenterology.

[5]  Chien-Jen Chen,et al.  Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. , 2016, Gastroenterology.

[6]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[7]  E. De Clercq.  Current treatment of hepatitis B virus infections , 2015, Reviews in medical virology.

[8]  E. Swenson,et al.  Prevention of neonatal hepatitis B virus transmission. , 2014, Journal of clinical gastroenterology.

[9]  M. LeFevre.  Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement , 2014 .

[10]  C. Trépo,et al.  A brief history of hepatitis milestones , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[11]  H. Hann,et al.  Then and now: the progress in hepatitis B treatment over the past 20 years. , 2014, World journal of gastroenterology.

[12]  N. Walker,et al.  The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. , 2013, Vaccine.

[13]  Dexter Kozen,et al.  New , 2020, MFPS.

[14]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[15]  Chien-Jen Chen,et al.  Natural history of chronic hepatitis B REVEALed , 2011, Journal of gastroenterology and hepatology.

[16]  Chien-Jen Chen,et al.  Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Wild,et al.  A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. , 2009, Cancer letters.

[18]  Chien-Jen Chen,et al.  Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. , 2009, Journal of the National Cancer Institute.

[19]  G. Dore,et al.  Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden , 2009, Journal of viral hepatitis.

[20]  Chien-Jen Chen,et al.  Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma , 2008, Journal of the National Cancer Institute.

[21]  Colin W Shepard,et al.  Hepatitis B virus infection: epidemiology and vaccination. , 2006, Epidemiologic reviews.

[22]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[23]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[24]  Fangjun Zhou,et al.  A mathematical model to estimate global hepatitis B disease burden and vaccination impact. , 2005, International journal of epidemiology.

[25]  J. Groopman,et al.  Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. , 2005, Cancer biomarkers : section A of Disease markers.

[26]  M. Kane.  Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  From the Centers for Disease control and Prevention. Effectiveness of a middle school vaccination law--California, 1999-2001. , 2001, JAMA.

[28]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[29]  Y. Ko,et al.  Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. , 1997, Pediatrics.

[30]  K. Ōkōchi,et al.  Observations on Australia Antigen in Japanese , 1993, Vox sanguinis.

[31]  R. Peto.  Carcinogenesis as a multistage process--evidence from human studies. , 1982, IARC scientific publications.

[32]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[33]  F. Galibert,et al.  Biosynthesis of hepatitis B virus surface antigen in Escherichia coli , 1980, Nature.

[34]  R. Purcell,et al.  Type B hepatitis: a review of current prospects for a safe and effective vaccine. , 1980, Reviews of infectious diseases.

[35]  D. Trichopoulos,et al.  HEPATITIS B AND PRIMARY HEPATOCELLULAR CARCINOMA IN A EUROPEAN POPULATION , 1978, The Lancet.

[36]  F. Gyorkey,et al.  Experimental carcinoma of liver in macaque monkeys exposed to diethylnitrosamine and hepatitis B virus. , 1977, Journal of the National Cancer Institute.

[37]  E. Lustbader,et al.  HOST RESPONSES TO HEPATITIS-B INFECTION IN PATIENTS WITH PRIMARY HEPATIC CARCINOMA AND THEIR FAMILIES A Case/Control Study in Senegal, West Africa , 1976, The Lancet.

[38]  M. Hilleman,et al.  Vaccine against human hepatitis B. , 1976, JAMA.

[39]  R. Purcell,et al.  Hepatitis B virus infection in chimpanzees: titration of subtypes. , 1975, The Journal of infectious diseases.

[40]  W. Szmuness,et al.  A case/control study of the association between primary liver cancer and hepatitis b infection in senegal , 1975, International journal of cancer.

[41]  B. Larouze,et al.  ANTIBODY TO HEPATITIS-B CORE ANTIGEN IN PATIENTS WITH PRIMARY HEPATIC CARCINOMA , 1975, The Lancet.

[42]  G. Klatskin.  Persistent HB antigenemia: associated clinical manifestations and hepatic lesions. , 1975, The American journal of the medical sciences.

[43]  F. Chisari,et al.  Transmission of type B viral hepatitis to chimpanzees. , 1973, The Journal of infectious diseases.

[44]  S. Sherlock,et al.  Cell-mediated Immunity in Patients Positive for Hepatitis-associated Antigen , 1972, British medical journal.

[45]  C. Vogel,et al.  Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma. , 1970, Lancet.

[46]  A. Sutnick,et al.  Australia antigen and hepatitis. , 1970, British medical journal.

[47]  A. Sutnick,et al.  Australia antigen and hepatitis. , 1970, The New England journal of medicine.

[48]  A M Prince,et al.  An antigen detected in the blood during the incubation period of serum hepatitis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Alter,et al.  A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.

[50]  A. Prince,et al.  ANICTERIC HEPATITIS IN KOREA. II. SERIAL HISTOLOGIC STUDIES. , 1964, Archives of internal medicine.